A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the SQ Grass SLIT-tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the SQ Grass SLIT-tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2015

At a glance

  • Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
  • Indications Allergic rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Pharmacodynamics; Registrational
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 19 May 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 09 Feb 2015 According an ALK-Abello media release, regulatory filing of GRAZAX in Russia is expected in 2015/2016.
    • 29 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top